Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
Neurocrine Biosciences announced publication of KINECT-PRO Phase 4 results showing INGREZZA significantly improved patient-reported quality of life and functionality in tardive dyskinesia patients. Approximately 58% of patients met the threshold for symptomatic remission at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity.
Key figures
- Drug Name
- INGREZZA (valbenazine)
- Phase Of Trial
- Phase 4
- Patients enrolled
- 59
- Efficacy analysis n
- 45
- Aims mean change overall
- -6.8
- Tdis mean change overall
- -8.0
- Patients completed week 24
- 52
- Symptomatic remission rate
- 58%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.